ArticleCancer chemotherapy and pharmacology2018

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Boaz Mendzelevski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.